JP2024527001A5 - - Google Patents
Info
- Publication number
- JP2024527001A5 JP2024527001A5 JP2024504491A JP2024504491A JP2024527001A5 JP 2024527001 A5 JP2024527001 A5 JP 2024527001A5 JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024527001 A5 JP2024527001 A5 JP 2024527001A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- dose
- aniflorumab
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225974P | 2021-07-27 | 2021-07-27 | |
| US63/225,974 | 2021-07-27 | ||
| US202163254663P | 2021-10-12 | 2021-10-12 | |
| US63/254,663 | 2021-10-12 | ||
| PCT/EP2022/070860 WO2023006700A1 (en) | 2021-07-27 | 2022-07-26 | Treatment of lupus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527001A JP2024527001A (ja) | 2024-07-19 |
| JP2024527001A5 true JP2024527001A5 (cg-RX-API-DMAC7.html) | 2025-08-05 |
Family
ID=83059135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504491A Pending JP2024527001A (ja) | 2021-07-27 | 2022-07-26 | ループスの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250326850A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4377349A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527001A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240038773A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022317215A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226744A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310241A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340245A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006700A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD1120170S1 (en) * | 2024-03-28 | 2026-03-24 | Karsten Manufacturing Corporation | Golf club head |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| PT2418220T (pt) | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| ES2643237T3 (es) | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| SMT201700063T1 (it) | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
| CN104603152A (zh) * | 2012-06-13 | 2015-05-06 | 米迪缪尼有限公司 | 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
-
2022
- 2022-07-26 AU AU2022317215A patent/AU2022317215A1/en active Pending
- 2022-07-26 TW TW111127870A patent/TW202340245A/zh unknown
- 2022-07-26 IL IL310241A patent/IL310241A/en unknown
- 2022-07-26 CA CA3226744A patent/CA3226744A1/en active Pending
- 2022-07-26 US US18/291,671 patent/US20250326850A1/en active Pending
- 2022-07-26 KR KR1020247006291A patent/KR20240038773A/ko active Pending
- 2022-07-26 JP JP2024504491A patent/JP2024527001A/ja active Pending
- 2022-07-26 EP EP22758427.3A patent/EP4377349A1/en active Pending
- 2022-07-26 WO PCT/EP2022/070860 patent/WO2023006700A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4114465B1 (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| TW202400234A (zh) | 使用fcrn拮抗劑治療大疱性類天皰瘡之方法 | |
| AU2021356122B2 (en) | Treatment of flares in lupus | |
| JP2024518735A5 (cg-RX-API-DMAC7.html) | ||
| US20250002589A1 (en) | Treatment of cutaneous lupus erythematous | |
| TW202308691A (zh) | 狼瘡性腎炎之治療 | |
| JP2024519196A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516886A5 (cg-RX-API-DMAC7.html) | ||
| US20250002591A1 (en) | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients | |
| KR20240038773A (ko) | 루푸스의 치료 | |
| CN121127499A (zh) | 狼疮的治疗 | |
| CN117337305A (zh) | 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制 | |
| JP2025533978A (ja) | ループスの治療 | |
| EA052183B1 (ru) | Лечение кожной красной волчанки | |
| CN117677638A (zh) | 狼疮的治疗 | |
| JP2023548848A (ja) | ループスを処置するための方法および組成物 | |
| HK40087032B (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| HK40087032A (en) | Anti-ifnar1 dosing regime for subcutaneous injection |